Figure 4: A perspective study of the accuracy of serum HCMV-miR-US4-1 levels as a biomarker to predict the outcome of IFNα therapy for individual CHB patients. | Scientific Reports

Figure 4: A perspective study of the accuracy of serum HCMV-miR-US4-1 levels as a biomarker to predict the outcome of IFNα therapy for individual CHB patients.

From: Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNα treatment in chronic hepatitis B patients

Figure 4

(a) A box showing the sensitivity and specificity of the serum HCMV-miR-US4-1-based biomarker. (b) A scatter diagram showing the accuracy of serum HCMV-miR-US4-1 levels as a biomarker for predicting the efficacy of IFNα therapy for individual CHB patients.

Back to article page